Stockwinners Market Radar for May 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:58 EDT Four Corners Property Trust acquires two Fast Pace Health properties for $4.9M - Four Corners Property Trust announces the acquisition of two Fast Pace Health properties for $4.9M. Fast Pace Health is an urgent care provider with more than 200 healthcare centers throughout the United States. The properties are newly constructed and located in strong retail corridors in Indiana and Louisiana and are occupied under long-term, net leases. The transaction was priced at a cap rate in range with previous FCPT transactions.

18:28 EDT Microsoft CMO sells $1.59M in common stock - In a regulatory filing, Microsoft disclosed that its CMO Christopher Capossela sold 5.1K shares of common stock on May 16th in a total transaction size of $1.59M.

17:58 EDT Taylor Morrison Director Lyon sells $6.8M in company shares - William Lyon, a director at Taylor Morrison Home, disclosed in a regulatory filing that he had sold 153,615 shares of company stock at $44.07 per share on May 16 for a total transaction amount of $6,769,936.

17:25 EDT FaZe Holdings appoints CFO Christoph Pachler to additional COO role - FaZe Holdings appointed Christoph Pachler, currently CFO, to the additional role of COO of FaZe Holdings and Erik Anderson to President of FaZe Clan. Pachler joined FaZe Holdings in September 2022 as CFO. Erik Anderson joined FaZe Clan in 2016 and previously served as head of esports. Zach Katz has resigned from his position as President and COO to explore other business opportunities. His resignation is effective May 31.

17:12 EDT Paramount director buys $2.5M in common stock - In a regulatory filing, Paramount disclosed that its director Shari Redstone bought 165K shares of common stock on May 16th in a total transaction size of $2.5M.

17:02 EDT Community Healthcare appoints William Monroe IV to CFO - Community Healthcare (CHCT) announced that its board of directors appointed William Monroe IV to be the company's CFO, effective as of June 1. David Dupuy, the company's CEO, said, "On behalf of the Company, we are excited to welcome Bill as our Chief Financial Officer. Bill's experience demonstrates a deep understanding of our industry, and I am confident that he is an excellent choice for this role. We look forward to working with Bill." Monroe has served as managing director of the healthcare investment banking group at Truist Securities (TFC) in Atlanta.

16:51 EDT Evofem announces 1-for-125 reverse stock split - Evofem announced a 1-for-125 reverse stock split of the company's common stock, which was approved by the stockholders of the company at the special meeting of stockholders held on March 15. The reverse stock split is intended to ensure the company has a sufficient number of authorized shares of common stock to cover the number of common shares underlying the company's financial instruments on a fully-diluted basis. The 1-for-125 reverse stock split will automatically convert 125 current shares of the Company's common stock into one share of common stock.

16:45 EDT Snowflake up 3% at $179 after The Information report on Neeva talks

16:37 EDT Republic First Bancorp receives noncompliance notification from Nasdaq - Republic First Bancorp announced that Nasdaq notified the company that because the company's Form 10-Q for the three months ended March 31 was not timely filed with the SEC, the company did not satisfy Nasdaq Listing Rule 5250 and that the Nasdaq hearings panel would consider the additional deficiency in its deliberations regarding the company's continued listing. The company previously presented for the panel's review the company's plan to file the Form 10-Q with the SEC by June 30 and thereby evidence full compliance with the filing requirement.

16:26 EDT NYSE to suspend trading in Cloopen Group, start delisting process - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the American depositary shares of Cloopen Group Holding Limited - ticker symbol RAAS - from the NYSE. Trading in the company's ADSs will be suspended immediately. NYSE Regulation reached its decision that the company's ADSs are not suitable for listing, because the company is a late filer and has not filed with the Securities and Exchange Commission its annual reports on Form 20-F for the years ended December 31, 2021 and December 31, 2022 and current report on Form 6-K for the half year ended June 30, 2022. The company informed the NYSE that it will not be able to complete its Delayed Filings by May 17, 2023, which is the maximum time allowed under Section 802.01E of the NYSE's Listed Company Manual. The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the ADSs upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision.

16:25 EDT NanoString responds to decision of the Regional Court of Munich - NanoString Technologies (NSTG) responded to the Regional Court of Munich's recent decision finding that NanoString's CosMx Spatial Molecular Imager, when used to detect RNA targets, infringes the German part of the European patent 2794928B1. The Munich court granted 10x Genomics (TXG) and President and Fellows of Harvard College the right to enforce an injunction against use of the CosMx SMI instrument for RNA detection in Germany. NanoString believes the Munich court came to an erroneous conclusion and will appeal the decision. The scope and impact of the Munich's court's decision is limited solely to Germany. In addition, the decision does not apply to the use of the CosMx SMI instrument for detection of proteins, which NanoString will continue to offer and support. "We respectfully disagree with the recent decision of the Regional Court of Munich," said Brad Gray, President and CEO of NanoString. "We continue to believe that 10x's claims are without merit. The CosMx SMI is fundamentally different from any other spatial biology platform on the market, offering capabilities that far exceed those of any other spatial analysis system, including any offered by 10x. We believe 10x's actions with respect to NanoString's breakthrough CosMx SMI system wrongly stifle competition and threaten to impede critical research by German scientists. NanoString will continue to pursue all legal avenues to vigorously defend against 10x's claims. We believe we will be vindicated on appeal in the immediate case and are confident in our arguments before the German Federal Patent Court where we are seeking a ruling to invalidate the patent in the nullity action." NanoString is challenging the asserted patent's validity through a parallel nullity action with the German Federal Patent Court in Munich. A decision in the nullity action is expected following a hearing scheduled for May 2024.

16:21 EDT New Relic rises after WSJ says PE firms in takeover talks - Shares of New Relic (NEWR) jumped about 11% to close at $83.84 and are up fractionally in after-hours trading after The Wall Street Journal's Laura Cooper reported, citing sources, that private-equity firms Francisco Partners and TPG (TPG) are working together on a $5B-plus deal to acquire the company. A deal, if one is reached, may be announced in the "next few weeks," the report added.

16:15 EDT 10x Genomics wins permanent injunction against NanoString's CosMx products - 10x Genomics (TXG) has won an injunction in its patent litigation against NanoString Technologies (NSTG) and NanoString Technologies Germany. The Munich Regional Court issued a permanent injunction that - once provisionally enforced against a security bond - requires NanoString to stop selling and supplying the CosMx Spatial Molecular Imager instruments as well as CosMx reagents for RNA detection in Germany. The Munich Regional Court issued the injunction based on its finding that the CosMx products infringe European Patent Number 2794928B1, which relates to in situ detection of analytes. In its decision, the Munich Regional Court referenced an earlier preliminary opinion by the German Federal Patent Court finding the asserted claims of the patent valid. 10x Genomics filed its patent infringement lawsuit against NanoString in Germany in March 2022.

16:12 EDT ViaSat CEO provides outlook - ViaSat CEO Mark Dankberg comented, "We ended FY2023 with several positive developments and increasing momentum across all of our businesses. ViaSat-3 EMEA is expected to launch later this calendar year and enter commercial service around the beginning of FY2025, due to a longer orbit-raising duration. For the full year FY2024 on a stand-alone basis without giving effect to the pending Inmarsat acquisition, we expect Adjusted EBITDA from continuing operations to grow in the high single digits to low double digits YoY - despite more than $60M of incremental, global ViaSat-3 operating expenses ahead of entry into commercial service. Cash flow from continuing operations is also expected to improve YoY driven by Adjusted EBITDA growth and an improvement in working capital. FY2024 capital expenditures are anticipated to be flat compared to FY2023, with the final ViaSat-3 Americas launch related payments having shifted between the fiscal years. Our investment mix is expected to become more success-based as we return to net subscriber growth in our U.S. fixed broadband business over the course of FY2024...We expect Q1 FY2024 to be impacted by launch-related costs for ViaSat-3 Americas, increased advertising and ground network expenses, seasonality in our government segment and IFC services and continued bandwidth constraints in U.S. fixed broadband prior to ViaSat-3 Americas entering commercial service. The quarterly profile of revenue and Adjusted EBITDA is expected to improve sequentially throughout the year due to expected equipment delivery and aircraft activations in IFC and resumption of net growth in the U.S. fixed broadband business, offset to some extent by expenses associated with additional ground network activation and the launch of ViaSat-3 EMEA. Longer term (on a stand-alone basis without giving effect to the pending Inmarsat acquisition), we expect to achieve faster growth in our continuing operations in FY2025, as we scale into the new ViaSat-3 constellation. We believe that we would achieve our stand-alone FY2025 target of doubling revenue and more than doubling continuing operations Adjusted EBITDA relative to FY2020. We would also expect to see capital expenditures continue to decline, with lower satellite-related investments partially offset by success-based expenditures. Our recent ViaSat-3 Americas launch was an important step towards a free cash flow turning point, which we target on a stand-alone basis in early calendar 2025".

16:09 EDT DLocal boosts headcount by 36% year-over-year to 763 employees in Q1 - "We continue to make disciplined investments in our infrastructure and our team to support our long term ambition. During Q1 2O23, we increased our headcount by 36% year-over-year to 763 employees. We have consistently maintained an Adjusted EBITDA over gross profit above 70% in the past nine quarters. However, we are still a young company in growth mode and we believe that over the long-term, there are opportunities to deliver operating leverage. Our excellent results in the first quarter, combined with our strong cash generation, give us even more confidence in our winning strategy in emerging markets. We are very excited about the massive opportunity ahead of us and we remain focused on executing our long-term strategy." said Sebastian Kanovich.

16:08 EDT Kyndryl, SAP announce expanded strategic partnership - Kyndryl (KD) announced an expanded strategic partnership with SAP (SAP) focused on developing new solutions to help customers solve their most complex digital business transformation challenges. Under their expanded collaboration, the companies have leveraged SAP Business Transformation Center and ERP systems know-how, along with Kyndryl's deep expertise in data, application migration, and modernization services to chart an efficient and cost-effective path to the cloud for customers. Specifically, Kyndryl and SAP collaborated on a digital blueprint capability that enables customers and partners to strategically assess, define and outline their migration and transformation plan for their transition from existing SAP ERP systems to SAP S/4HANA. "SAP Business Transformation Center has been instrumental to our own internal transformation at Kyndryl," says Michael Bradshaw, Chief Information Officer, Kyndryl. "Through this experience and collaboration with SAP, we've strengthened our expertise in application and data migration while developing capabilities to deliver enhanced services to our customers."

16:00 EDT New Relic jumps 11% to $83.97 on acquisition speculation by WSJ

14:57 EDT Galera granted orphan status for pancreatic cancer treatment - The FDA granted Galera Therapeutics orphan status for rucosopasem manganese, its potential treatment of pancreatic cancer. Reference Link

14:40 EDT Nasdaq says Goldenbridge Acquisition shares will be suspended - The business combination of Goldenbridge Acquisition (GBRG) and SunCar Technology Group closed today, the Nasdaq said in a statement. Following the completion of the business combination, the company's common stock and warrants will undergo a name, symbol, and CUSIP number change and the company's rights and units will be suspended from trading, the Nasdaq added. In addition to these changes, the combined company has re-domiciled from the British Virgin Islands to the Cayman Islands. These actions will become effective on May 18. Shares of Goldenbridge Acquisition are down 34% to $4.65 in

14:20 EDT Heritage to enter recreational cannabis-infused beverage market in Canada - Heritage Cannabis Holdings announces that it is entering the recreational cannabis-infused beverage market in Canada. Through a sales and distribution agreement with a leading producer of beverage products, BevCanna, Heritage will utilize its distribution channels and penetration with the provincial boards to bring some of the top performing beverages to market across the country. "Through a partnership with BevCanna, Heritage will help boost the distribution and accelerate sales of BevCanna products, including one of Canada's favourites - Keef Cola. This partnership introduces a new vertical and revenue stream for Heritage in an efficient manner, using our well established distribution network in Canada," said David Schwede, CEO of Heritage. "Cannabis-infused beverages are a strong volume product with solid margins, and will be a great addition to our portfolio of offerings."

14:17 EDT San Francisco City announces $230M opioid settlement with Walgreens - San Francisco City Attorney David Chiu announced a $230M settlement with Walgreens Boots Alliance to resolve claims over opioids. "The court found Walgreens substantially contributed to the opioid epidemic and created a public nuisance in San Francisco. Walgreens over-dispensed opioids without due diligence and failed to report suspicious orders as required by law," Chiu announced.

14:00 EDT BlackBerry shares advance after announcing access to QNX developer tools - Shares of BlackBerry are up 16c or approximately 3% to $5.23 per share in afternoon trading on Wednesday, after announcing, in an earlier statement: "BlackBerry Limited announced the early access release of QNX Software Development Platform, SDP, 8.0 to enable automakers and IoT systems developers to deliver more powerful products at lower costs, while maintaining the unparalleled safety, security and reliability standards that QNX technology has long been known for. Powered by its new next generation QNX operating system OS , the company's highest performance, safe and secure embedded OS ever, SDP 8.0 is designed to realize the performance potential of the increasing number of multi-core processors that automakers and IoT systems developers are selecting for their products and is the result of intense R&D work utilizing BlackBerry QNX's leading IP and unique experience in high performance EDGE computing." Reference Link

13:41 EDT Maximus jumps over 2% after announcing multiple award BPA with IRS

13:30 EDT Bausch Health says U.S. District Court upholds final judgment for Xifaxan - Bausch Health Companies, and its gastroenterology business Salix Pharmaceuticals, announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied Norwich Pharmaceuticals' motion to modify the Court's final judgment that prevents the U.S. Food and Drug Administration from approving Norwich's abbreviated new drug application, or ANDA, for Xifaxan 550 mg before Oct. 2, 2029. As a result of this decision, Norwich's ANDA cannot be approved until Oct. 2, 2029, the company stated. "This decision is important for patients who continue to depend on a proven and highly effective drug to treat gastro-intestinal disorders. It is our long-standing position that the Xifaxan patent claims are valid and infringed by Norwich's ANDA. We will continue to advocate for the safety of patients who have benefited from the continued access to Xifaxan, and we look ahead to the appeal process," Bausch Health CEO Thomas Appio stated. "To date, Norwich has not received tentative or final approval of its ANDA from the FDA," the company added.

13:13 EDT PTC Therapeutics says APHENITY trial achieved primary endpoint with sepiapterin - PTC Therapeutics announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria, or PKU. The placebo-controlled portion of the study included 98 patients in the primary analysis population. The mean percent Phe reduction in sepiapterin treated patients was 63%. In the subset of classical PKU patients, the mean percent Phe reduction was 69%. Minimal reductions in Phe levels were observed in the placebo treated patients resulting in a highly statistically significant sepiapterin treatment benefit. Sepiapterin was generally well tolerated with no serious adverse events.

13:09 EDT Imax, Kinepolis expand partnership with eight IMAX with Laser systems - Kinepolis and Imax announced a global expansion of their longstanding partnership with eight state-of-the-art IMAX with Laser systems across Europe, Canada and the U.S. The agreement includes four new locations across Europe - including France, Belgium, Spain, and the first-ever IMAX system in Luxembourg - as well as a new location in Michigan and Ontario and two upgraded systems in Ontario. The announcement was made on Wednesday from the 2023 Cannes Film Festival. The new agreement nearly doubles Imax's footprint with the Belgium-based international exhibitor and its subsidiaries, including a first-time collaboration with MJR Cinemas, a U.S. subsidiary of Kinepolis. At present, Imax partners with Kinepolis and its subsidiaries on seven locations currently in operation across Belgium and Canada. Under the agreement, Imax will enter new territories with Kinepolis in Canada, Belgium, France and Spain, and Luxembourg. The deal was established as an amalgamation of signings with Kinepolis and their wholly owned subsidiaries, MJR Digital Cinemas and Landmark. MJR Digital Cinemas operates locally in the Metro Detroit area in Michigan, while Landmark operates theatres across several provinces in Canada. The eight new and upgraded locations for Kinepolis and its subsidiaries will be equipped with IMAX with Laser, Imax's most advanced theater experience.

13:03 EDT ServiceNow, Nvidia announce partnership - ServiceNow (NOW) and Nvidia (NVDA) announced a partnership to develop "powerful, enterprise-grade generative AI capabilities that can transform business processes with faster, more intelligent workflow automation." Using Nvidia software, services, and accelerated infrastructure, ServiceNow is developing custom large language models trained on data specifically for its ServiceNow Platform, the company stated. "As adoption of generative AI continues to accelerate, organizations are turning to trusted vendors with battle-tested, secure AI capabilities to boost productivity, gain a competitive edge, and keep data and IP secure. Together, Nvidia and ServiceNow will help drive new levels of automation to fuel productivity and maximize business impact," said CJ Desai, president and COO of ServiceNow.

12:00 EDT Gates Industrial falls -8.8% - Gates Industrial is down -8.8%, or -$1.18 to $12.16.

12:00 EDT ProPetro Holding rises 14.0% - ProPetro Holding is up 14.0%, or 91c to $7.38.

12:00 EDT Alerian Midstream Energy Index rises 1260.3% - Alerian Midstream Energy Index is up 1260.3%, or $446.48 to $481.91.

11:53 EDT Conduent Transportation to implement transit ticketing system in Victoria - Conduent Transportation announced its subsidiary, a partnership of Conduent and Convergint, was selected by the State of Victoria, Australia, to provide the next generation of the state's public transport ticketing system, called myki. "The companies will implement an advanced, contactless payment account-based transit ticketing system that will modernize the state's existing smartcard solution and offer riders an enhanced user experience. Under the contract, management of the existing system will begin in December 2023, and trials of the first phase of the new system are expected to start in 2024. The system will be designed to reach travelers in and beyond the greater Melbourne region and throughout Victoria. The expected value of the contract is in excess of $1 billion and is expected to last 15 years," the company stated earlier. This alert corrects a previous version with an error in the headline.

11:49 EDT Jack in the Box: Trends in Q3 remain 'favorable,' momentum continuing - Comments taken from Q2 earnings conference call.

11:25 EDT TJX sees Q2 pretax profit margin 10.6%-10.8%

11:12 EDT Uber customers now able to use phone to request ride without app - During GO-GET 2023, Uber's annual product showcase, the company presented new products and features that "are designed to make your life a little easier." Uber highlighted family profiles and introduced teen accounts on Uber - "built for parents and caretakers of 13-17 year olds to save precious time with peace of mind." Teen accounts for rides will be available beginning on May 22 in select cities in the U.S. and Canada. Plus, teen accounts will soon be available on Uber Eats. The company also announced "Uber Car Seat," allowing parents and caregivers to request and reserve a ride with Nuna's RAVA car seat. "We often hear from riders about family members who want to use Uber but aren't as familiar with navigating a smartphone. Now, everyone in the family can enjoy the same effortless Uber experience, even without the app. For U.S. customers it's as easy as dialing 1-833-USE-UBER, 1-833-873-8237, toll-free, to speak with an agent in English or Spanish, and request a ride on-demand or reserve one for a future trip," the company said. Uber also announced group grocery orders on Uber Eats that lets users invite participants to add their own items to a shared cart, set deadlines for when to add their must-haves, and even automatically split the bill at most stores for a hassle-free experience. In select cities, customers will also be able to invite others to add their addresses on a group trip, and soon, the Uber app will automatically update the stops to pick each person up according to the most efficient route. With summer approaching, Uber will also offer the opportunity to book a boat directly via the Uber app. Boat allows for up to 8 people to cruise to popular destinations around the island of Mykonos. Reference Link

11:02 EDT ServiceNow announces multiyear North American partnership with NHL - ServiceNow and the National Hockey League announced a multiyear North American partnership. "As an Official NHL Partner, ServiceNow will enhance game day operations, streamline employee productivity, and support new connected fan experiences," the company stated. "ServiceNow helps fundamentally change the way organizations operate-including one of the largest, most successful sports leagues in the world. Under Commissioner Bettman, the NHL has embraced this potential wholeheartedly. Our collaboration marks the most in-depth transformation of a sports league through ServiceNow to-date-and it's only just beginning. We're looking forward to helping the NHL take the next step toward improving workflow processes," added Bill McDermott, chairman and CEO at ServiceNow.

10:06 EDT FDA posts briefing documents for AdCom to review Intercept's obeticholic acid - The FDA is convening a meeting of the Gastrointestinal Drugs Advisory Committee on May 19 to discuss the benefits and risks of obeticholic acid, or OCA, 25 mg for treatment of non-alcoholic steatohepatitis, or NASH, with fibrosis put forward by applicant Intercept Pharmaceuticals. In briefing documents prepared by FDA staff that were posted ahead of the meeting, staff wrote: "Trial results for obeticholic acid indicate it causes multiple offtarget effects making it challenging to develop and implement effective risk mitigation. The Committee will be asked to discuss whether the available efficacy data for OCA 25 mg on a single histologic endpoint are sufficient to justify/counterbalance the observed risks in the proposed population." Reference Link

10:00 EDT Doximity falls -8.1% - Doximity is down -8.1%, or -$2.73 to $31.14.

10:00 EDT Kyndryl Holdings falls -14.8% - Kyndryl Holdings is down -14.8%, or -$2.13 to $12.25.

10:00 EDT Triumph Group rises 13.3% - Triumph Group is up 13.3%, or $1.40 to $11.91.

09:49 EDT United Homes Group Inc trading resumes

09:47 EDT Skeena Resources falls -6.1% - Skeena Resources is down -6.1%, or -36c to $5.54.

09:47 EDT Western Alliance rises 10.7% - Western Alliance is up 10.7%, or $3.39 to $34.98.

09:47 EDT Alerian Midstream Energy Index rises 1259.6% - Alerian Midstream Energy Index is up 1259.6%, or $446.22 to $481.64.

09:41 EDT Exela Technologies trading resumes

09:37 EDT Ohmyhome Ltd trading resumes

09:34 EDT United Homes Group Inc trading halted, volatility trading pause

09:32 EDT ECB fines Goldman EUR 6.3M for misreporting capital needs - The European Central Bank has imposed an administrative penalty of EUR 6.63M on Goldman Sachs Bank Europe after the bank "reported wrongly calculated risk-weighted assets for credit risk." In 2019, 2020 and 2021, for eight consecutive quarters, the bank reported lower risk-weighted assets for credit risk than it should have done, the ECB said in a statement. This occurred because the bank misclassified corporate exposures and applied a lower risk-weight to them than what banking rules prescribe, the agency added. Reference Link

09:26 EDT Grove announces new retail partnerships with Kroger, Costco and Hannaford - Grove Collaborative Holdings (GROV) and Certified B Corp announced another significant retail expansion for Grove Co., its flagship home care brand. The Company added three retailers: Kroger (KR), Costco (COST) and Hannaford - marking further progress in its omni-channel distribution expansion strategy. The latest retail additions brings the Company's retail footprint to over 5,700 brick-and-mortar stores. "We are excited about the continued momentum in our omni-channel strategy with this latest expansion into Kroger, Costco and Hannaford stores," said Stuart Landesberg, co-founder and CEO of Grove Collaborative. "Meeting our customers where they shop is critical to our objective of making planet-friendly household essentials as accessible as possible. We remain focused on delivering on our long-term capital efficient growth strategy by continuing to put our products on more shelves and in the hands of more consumers."

09:21 EDT Amwell appoints Kathy Weiler as Chief Commercial and Growth Officer - Amwell announced the appointment of Kathy Weiler as Executive Vice President, Chief Commercial and Growth Officer, effective June 1, 2023. As a member of Amwell's executive leadership team, Weiler will lead the company's growth strategy, driving strategic initiatives and leading the business development, sales and account management, commercial enablement, marketing, and strategic and channel partnerships teams. Weiler will partner with Amwell clients to help them achieve greater clinical, operational and financial outcomes by leveraging the Amwell Converge(TM) platform to deliver digitally enabled hybrid care solutions at scale. This press release features

09:18 EDT Edible Garden announces launch of Garden Starters - Edible Garden AG announced the launch of Garden Starters, a featured display for the Company's potted herbs and basil bowls that can be planted in a consumer's home garden, at all Meijer retail locations across the Midwest as well as all Wakefern/Shoprite retail locations across the Northeast. Jim Kras, Chief Executive Officer of Edible Garden, stated, "We are excited to broaden our Garden Starters distribution to all Wakefern/Shoprite retail locations throughout the Northeast. We first introduced this initiative at Meijer retail locations in the Midwest, just prior to Mother's Day, to address the growing interest in our potted herbs and their suitability for home gardens. Considering that 35% of American households grow a portion of their own food, Edible Garden's sustainably produced, herbs, and produce, have become popular choices amongst consumers that are looking to make their food taste better. Garden Starters presents an opportunity for consumers to purchase Edible Garden potted herbs for their home gardens. By making the potted herbs available alongside our cut herbs and sustainably grown produce in the same supermarket section, we provide the utmost convenience for customers."

09:17 EDT Sabre announces agreement with SKY Airline - Sabre announced a new multi-year agreement with SKY Airline, a low-cost Chilean airline with flights to over 40 destinations in 8 countries across the Americas. Under the agreement, the airline will expand the content it distributes through the Sabre GDS and migrate to SabreSonic passenger service system, PSS. SKY Airline will distribute its full inventory of flights and services through Sabre's extensive global network of travel buyers, expanding its reach and allowing agencies to access the content without any surcharge. This will allow Sabre-connected travel agencies to deliver even more choice and value to their travelers. Additionally, the agreement with Sabre will allow SKY to deliver a tailored customer experience to capture new revenue opportunities through the use of SabreSonic PSS, which is scheduled to be implemented in 2024. Sabre's robust PSS will help SKY grow domestically and internationally through merchandising, codeshare agreements and alliance partners.

09:15 EDT eMagin trading resumes

09:13 EDT NeuroOne announces first case using Evo sEEG electrode in robotic neurosurgery - NeuroOne Medical Technologies announced the first clinical case using the Evo sEEG electrode in robotic neurosurgery. Performed by Dr. William Bingaman at Cleveland Clinic, the procedure was the first to utilize NeuroOne's Evo sEEG electrode, exclusively marketed in the U.S. by Zimmer Biomet, with Zimmer Biomet's ROSA One Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures. Dave Rosa, CEO of NeuroOne, commented, "This clinical case utilizing our minimally invasive and high-definition electrode technology with ROSA One Brain is a major milestone in NeuroOne's partnership with Zimmer Biomet. Now that Zimmer Biomet has commenced U.S. distribution of our Evo sEEG electrodes, this case study confirms the synergistic use of our product with Zimmer Biomet's robotics platform which was the foundation of our interest to partner with Zimmer Biomet."

09:08 EDT eMagin to be acquired by Samsung Display for $2.08 per share in cash - eMagin (EMAN) announced that the Company has entered into a definitive merger agreement with Samsung Display Co, a subsidiary of Samsung Electronics Co (SSNLF). Under the terms of the agreement, all outstanding shares of eMagin common stock on a fully diluted basis will be acquired for $2.08 per share in cash, in a transaction valued at approximately $218M. The purchase price represents a premium of approximately 10% to eMagin's closing stock price of $1.89 on May 16, 2023, and a premium of approximately 24% to eMagin's six-month volume-weighted average price of $1.68. "This agreement is a validation of our technical achievements to date including our proprietary direct patterning technology, provides a significant premium for our shareholders, and represents a win for our customers and employees," said Andrew G. Sculley, eMagin's Chief Executive Officer. "By teaming with Samsung Display, we will be able to achieve the full potential of our next-generation microdisplay technology with a partner that can provide the resources and expertise we will need to scale production. Moreover, our customers will benefit from resulting improvements to our production capabilities in terms of yield, efficiency, and quality control." eMagin's Board of Directors has unanimously approved the transaction and is recommending that eMagin's stockholders approve the transaction and adopt the merger agreement at a special meeting of stockholders to be called in connection with the transaction. The transaction is expected to close in the second half of 2023, subject to the approval by eMagin's stockholders, applicable regulatory approvals and other customary closing conditions. Until closing, eMagin and Samsung Display remain separate and independent companies.

09:06 EDT Nuvei selected by Radisson Hotel Group as its preferred payments partner - Nuvei Corporation announces that it has been selected to provide payments services to Radisson Hotel Group, an international hospitality operator with nine distinctive hotel brands and more than 1,100 hotels in operation and under development in EMEA & APAC. Radisson Hotel Group is leveraging Nuvei's global reach and extensive local networks to enhance its international online payments offering. This announcement is the latest from Nuvei as it continues to accelerate growth for international businesses in the travel and hospitality sectors. Philip Fayer, Nuvei Chair and CEO, commented: "We're excited to be partnering with another premier global operator in the hospitality industry. Radisson Hotel Group has a strong brand reputation for excellence which we are proud to be supporting during the booking process, an incredibly important touchpoint for any business with its customers. For an international operator like Radisson Hotel Group, with properties in multiple continents and customers all over the world, our global reach and agile technology drives success both locally and globally to accelerate growth."

09:03 EDT Ads-Tec and JOLT Energy extend fast charging collaboration in Europe & U.S. - ADS-TEC Energy and JOLT Energy announced an extension of their long-standing collaboration to deploy ultra-fast charging stations in major cities in Europe and the United States. JOLT has already ordered a high double-digit number of systems for 2023, and more orders are expected in support of JOLT's roll-out plan. The collaboration reflects the strong demand for a fast, convenient charging experience, especially in inner-city areas...Thomas Speidel, CEO, ADS-TEC Energy, said, "We are excited to further deepen our strategic collaboration with JOLT to pursue our common objective: Ultrafast charging at almost any location. Especially in inner-city areas, there is usually a lack of the required grid capacity and there is little available space. This is precisely what our charging solutions are ideally suited for, as they enable ultra-fast charging despite power-limited grid connections, take up little space and are easy to install. With their large battery storage capacity and multifunctionality, they are a valuable platform for the energy transition." Thomas Speidel, CEO, ADS-TEC Energy, said, "We are excited to further deepen our strategic collaboration with JOLT to pursue our common objective: Ultrafast charging at almost any location. Especially in inner-city areas, there is usually a lack of the required grid capacity and there is little available space. This is precisely what our charging solutions are ideally suited for, as they enable ultra-fast charging despite power-limited grid connections, take up little space and are easy to install. With their large battery storage capacity and multifunctionality, they are a valuable platform for the energy transition."

09:01 EDT Interlink Electronics approves 100,000 shares buyback program - Interlink Electronics announced that its board of directors has approved a program to buy back up to 100,000 shares of the Company's common stock. The program will commence on May 17 and is scheduled to terminate on May 15, 2024 or when the 100,000 share buyback limit is reached. The Company expects to finance the purchases with existing cash balances, which is not expected to have a material impact on capital levels.

08:50 EDT Conduent Transportation to implement transit ticketing system in Virginia - Conduent Transportation announced its subsidiary, a partnership of Conduent and Convergint, was selected by the State of Victoria, Australia, to provide the next generation of the state's public transport ticketing system, called myki. The companies will implement an advanced, contactless payment account-based transit ticketing system that will modernize the state's existing smartcard solution and offer riders an enhanced user experience. Under the contract, management of the existing system will begin in December 2023, and trials of the first phase of the new system are expected to start in 2024. The system will be designed to reach travelers in and beyond the greater Melbourne region and throughout Victoria. The expected value of the contract is in excess of $1 billion and is expected to last 15 years.

08:45 EDT eMagin trading halted, news pending

08:39 EDT Syla Technologies plans to double dividend to $1.04 from $0.52 per share - Based on management's current expectations for the Company's 2023 full year results of operations, the Company expects to double the dividend per share to be declared from $0.52 per share to $1.04 per share for the year ending December 31, 2023, compared to 2022. The Company expects to continue to increase dividends every year with a mid to long-term target of a dividend payout of 30% of net income.

08:37 EDT Syla begins preparations to establish employee stock repurchase plan - SYLA Technologies will begin preparations to establish an employee stock purchase plan. If adopted, the employee stock purchase plan would enable employees to purchase, at a discount, the Company's securities. The employee stock purchase plan is intended to enhance the Company's corporate value by giving employees a stronger perspective as investors and managers. The plan is also aimed at further enhancing employee benefits by providing a 20% incentive contribution in purchasing the Company's securities. The Company expects to launch the plan on or about July 1, 2023.

08:36 EDT Motus GI Holdings enters collaboration with IECED - Motus GI Holdings announced in collaboration with the Ecuadorian Institute of Digestive Diseases, IECED, initiation of a clinical evaluation of the Pure-Vu Gen 4 Gastro, which is designed for upper gastrointestinal bleeding procedures - an area of high unmet patient need. "We are excited to initiate this important clinical evaluation of the Pure-Vu Gen 4 Gastro with Dr. Carlos Robles-Medranda and the team at IECED. The focus of these procedures was aimed at evaluating the device's ability to improve a physician's visualization while identifying and treating upper GI bleeds. Dr. Robles-Medranda has already successfully conducted his first series of procedures utilizing the Pure-Vu Gen 4 Gastro and provided positive initial feedback on the device's performance. We plan to submit a 510(k) application to the U.S. FDA for the Pure-Vu Gastro device in Q4 of this year," commented Mark Pomeranz, Chief Executive Officer. "We believe this is a significant potential new market for the Pure-Vu platform."

08:35 EDT CN Energy subsidiary's plant renews business license for timber products - CN Energy Group announced that its wholly-owned subsidiary, Greater Khingan Range Forasen Energy Technology Tahe Biopower Plant, has recently received a renewed business license with authorization to process and sell timber products. The license will be mostly used by the Tahe Biopower Plant located at the Greater Khingan Range in Northeast China. The Company regards the renewed license as a milestone, as it enables the Company to collect and process forest residuals and wood wastes more effectively and efficiently, while leveraging its proprietary technologies to create higher value-add in a seamlessly integrated process. For instance, round logs with a diameter greater than 12 centimeters can be used to manufacture wood boards, while tree branches and twigs with a diameter less than 12 centimeters, as well as sawdust, can be processed for the production of activated carbon and biochar products and for gasification to generate clean and renewable electricity.

08:33 EDT Sientra announces FDA-clearance of novel Portfinder technology - Sientra announced that the Food and Drug Administration, FDA, has granted a 510(k) clearance for the Company's novel Portfinder technology. Portfinder is an electronic handheld device that allows for the subcutaneous location of ports in Sientra's Dermaspan and AlloX2 Pro tissue expanders. This new technology replaces the traditional dangle magnet mechanism and provides a more accurate port location with improved useability for clinicians. "The FDA's clearance of Portfinder marks another first for Sientra and reflects our ongoing commitment to innovation and improvement of the patient experience in reconstruction cases," said Ron Menezes, President and CEO of Sientra. "We look forward to commercializing this product and putting it in the hands of the most skilled plastic surgeons, our customers."

08:31 EDT Target: Pandemic feels 'further and further behind us'

08:21 EDT Xtract One selected by Sentara Health for weapons detection services - Xtract One Technologies announced its partnership with Sentara Health to provide weapons detection services at hospitals in Virginia, following a deployment of Xtract One's SmartGateway entry screening technology. The deployment at two hospitals was part of the evaluation for expansion to all 12 Sentara hospitals in Virginia and North Carolina.

08:16 EDT Siyata Mobile signs distribution agreement wth KPN Royal Dutch Telecom - Siyata Mobile signed a distribution agreement for its next-generation MCPTT solution with KPN Royal Dutch Telecom. The SD7 handsets and related accessories are now being offered by KPN with its KPN PTT service to medium and large government and enterprise clients.

08:14 EDT Candente Copper says Fortescue Metals exercises pre-emptive right - Candente Copper announced that Fortescue Metals Group, has exercised their pre-emptive right to maintain their shareholder's interest. As previously announced by the Company on April 27, 2023, the Company arranged a Private Placement with Whittle Equity to raise gross proceeds of $500,000 through the issuance of 2,777,777 Common Shares at a premium to market purchase price of $0.18 per Common Share. As a result of the private placement with Whittle, Nascent Exploration Pty Ltd., a wholly owned subsidiary of Fortescue Metals has exercised their pre-emptive right to subscribe for 1,984,000 Common Shares at a purchase price of $0.18 per Common Share for a total purchase price of $357,120 to maintain their shareholder's interest at 25.4%. Closing of the private placement with Whittle and Fortescue Metals is subject to the approval of the Toronto Stock Exchange and expected to occur on or before May 26, 2023. All securities issued in the private placement will be subject to a four month hold period.

08:13 EDT Target sees shrink reducing FY profitability by more than $500M vs. last year

08:12 EDT Lightspeed announces newest release of latest version of restaurant solution - Lightspeed Commerce announced the release of the latest version of its powerful restaurant solution: the Next Generation of Lightspeed Restaurant. This update, now available in the United States, revolutionizes restaurant operations by offering faster ordering and payments options on smartphones and by leveraging the power of data. "We are helping US restaurants reimagine the way they run their front of house operations, not only to improve efficiency but to help drive additional revenue and change the guest experience for the better," says Peter Dougherty, GM of Hospitality at Lightspeed. "Lightspeed is on a mission to radically change the restaurant industry, empowering restaurant operators with real-time insights at their fingertips."

08:11 EDT Target CEO sees shrink expense more than $1B higher vs. last year

08:11 EDT ShockWave Medical appoints Ballinger to board of directors - Shockwave Medical announced that Kevin Ballinger has joined its Board of Directors and will serve on Shockwave's Nominating and ESG Committee and the Compensation Committee of the Board. Ballinger, who is a recognized leader in the healthcare industry with over 25 years of professional experience, has served since July 2020 as President of Aldevron.

08:11 EDT Target CEO: Violent incidents increasing at stores, across retail industry - Comments taken from Q1 earnings conference call.

08:08 EDT Mullen Automotive vehicle production to begin in July at Mississippi center - Mullen Automotive announces vehicle production will begin in July 2023 at Mullen's Manufacturing Center in Tunica, Mississippi. Mullen's manufacturing group has partnered with NRTC Automation out of Birmingham, Alabama, for Class 3 assembly line installation and integration, which includes all robotics and automation systems for vehicle production. Recent capital expenditures in Tunica include addition of Automated Guided Vehicles to transport vehicles through assembly stations in the plant, installation of robotics, water test booth and end-of-line diagnostics. To date, the Company has received $279 million in purchase orders for Mullen Class 1 and Class 3 EV Vans and Trucks from Randy Marion Automotive Group. Randy Marion, based in North Carolina, is one of the largest commercial vehicle dealer groups in the U.S. "It's gratifying to see our Class 3 vehicle production line coming together in Tunica and even more validating to know we will have vehicles coming off the line and delivered to customers later this summer," said David Michery, CEO and chairman of Mullen Automotive.

08:06 EDT Sensus Healthcare's SRT-100 treatment shows promise treating MCTs in pets - Sensus Healthcare is announcing that its superficial radiation therapy SRT-100 system has shown promising results treating Cutaneous Mast Cell Tumors, MCTs, in pets. This new limited study, just published in the Journal of the American Veterinary Medical Association, demonstrates the potential effectiveness and safety of SRT treatment. Patient that presented with 2 mast cell tumors (MCTs; asterisk) on the lower eyelid and muzzle. Surgical option for the MCT of the eyelid was presented as enucleation. The objective of the study was to report preliminary findings of hypofractionated superficial radiotherapy for treatment of cutaneous mast cell tumors and report the acute and late toxicity associated with its use. Superficial radiation therapy was effective in the limited study population, and patients experienced minimal side effects for treatment of cutaneous MCTs.

08:06 EDT XPO announces proposed private offering of senior secured, unsecured notes - XPO intends to offer through one or more private placements $830 million in aggregate principal amount of senior secured notes due 2028 and $450 million in aggregate principal amount of senior unsecured notes due 2031. The Notes are being offered in addition to the previously announced proposed $700 million senior secured term loan facility. The company intends to use the net proceeds from the issuance of the Notes, together with the proceeds from the New Term Loan Facility and cash on hand, to repay term loan principal and accrued interest outstanding under its existing secured term loan facility and to pay fees, costs and expenses relating to the Notes and New Term Loan Facility. The remaining portion of the Existing Term Loan is expected to be repaid with cash on hand in the second quarter of 2023. The closing of the New Term Loan Facility and the terms thereof are subject to obtaining lender commitments, as well as market and other conditions, and there can be no assurance as to whether or when the New Term Loan Facility may be completed, or as to the actual size or terms thereof.

08:05 EDT ZIM Integrated announces $8M financing round in Spinframe - ZIM Integrated Shipping Services, along with other investors, announced the initial closing of an $8M financing round in Spinframe. ZIM led this investment as part of its strategy to invest in early-stage companies involved in the digitalization of supply chains who offer novel cutting-edge services with high growth potential. Spinframe develops vehicle-inspection systems based on artificial intelligence, or AI, computer vision, and machine-learning technologies, that create "Digital Twins" for vehicles throughout the supply chain and detect anomalies from the assembly line throughout the vehicle journey to the dealership and end customer.

08:03 EDT Oryzon Genomics to present trial in progress Phase Ib FRIDA study - Oryzon Genomics announced the presentation of the trial in progress FRIDA poster entitled Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia at the upcoming American Society of Clinical Oncology 2023 Annual Meeting, to be held in-person from June 2-6, 2023 at the McCormick Place in Chicago, Illinois. Dr. Amir Fathi, Director of the Leukemia Program at Massachusetts General Hospital, is the Principal Investigator of the study and first author of the poster. He will be recording a brief video summarizing the poster information and study status. Dr. Douglas V. Faller, Oryzon's Global Chief Medical Officer, will attend the poster presentation, which will take place during the Poster Discussion Session on Monday June 5 from 8:00 AM-11:00 AM within the Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant Session. FRIDA is an open-label, multicenter study of iadademstat plus gilteritinib for the treatment of patients with relapsed or refractory AML with FLT3mutations. The trial's primary objectives are to evaluate the safety and tolerability of iadademstat in combination with gilteritinib in patients with FLT3mut+ R/R AML and to establish the Recommended Phase 2 Dose for this combination. Secondary objectives include evaluation of the treatment efficacy, measured as the rate of complete remission and complete remission with partial hematological recovery, the duration of responses and the assessment of measurable residual disease. FRIDA will be conducted in 10-15 sites in the US. The study will enroll up to approximately 45 patients and if successful, the Company and FDA have agreed to hold a meeting to discuss the best plan to further develop this combination in this much in need AML population.

08:02 EDT IN8bio's DeltaEx Gamma-Detla T cells show potential targeting ovarian cancer - IN8bio announced positive preclinical data underscoring the potential of its DeltEx Gamma-Delta T cells to target and kill ovarian cancer. The data were featured in a poster presentation at the American Society of Cell & Gene Therapy 26th Annual Meeting and showed that DeltEx Gamma-Delta T cells were able to target and kill ovarian cancer cells, even in platinum-resistant and treatment-resistant cell lines. "These findings highlight the synergy of combining gamma-delta T cells with chemotherapy to target solid tumors, even outside the brain," said William Ho, CEO and co-founder of IN8bio. "We are encouraged by these data that suggest that a combination using DeltEx Gamma-Delta T cells may provide a promising new approach to treating patients with ovarian cancer."

08:01 EDT Ultragenyx receives FDA agreement to expand ongoing Phase 1/2 trial of GTX-102 - Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration, FDA, has reviewed and agreed to a protocol amendment to the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome that enables the company to harmonize dose ranges in the U.S. with those being used in ex-U.S. cohorts of the study. Outside of the U.S., the Phase 1/2 study has been actively enrolling and dosing patients in the expansion cohorts to verify the GTX-102 dose and treatment regimen that will be used in the Phase 3 program. "Agreement on the protocol amendment enables comparable dose ranges across all geographies and allows us to move forward rapidly to complete the study. We have begun working urgently to activate multiple study sites in the U.S. and plan to begin enrollment as quickly as possible," said Scott Stromatt, M.D., SVP and chief medical officer of neurology clinical development at Ultragenyx. "We are eager to expand the study in the U.S. to build on the encouraging data, which demonstrate important clinical activity across multiple functional domains impacted by Angelman syndrome with an acceptable safety profile."

07:36 EDT Electrovaya provides update on solid state hybrid battery technology - Electrovaya provided an update on its proprietary solid state lithium metal battery technology at its Electrovaya Labs division. Progress is ongoing in several areas: Multi-layer pouch cells have been developed, and they are amenable for scale up. A critical materials technology is the ionic conducting ceramic material. Electrovaya has initiated a program to synthesize the ceramic ionic conductor. A number of different synthesis routes are being developed, and the pouch cells are being fabricated using the Electrovaya-produced ceramic ion conducting material. The cell design is essentially anode-less. This allows higher volumetric energy density and lower cost. The cells have undergone very high charge and discharge-rates, and the pouch cells are amenable to such high rates. Design work on the production line is underway, and a prototype line is expected to be in place later in 2023. The target of this project is to double, if not triple, the volumetric energy density of the cell compared to a conventional lithium ion cell technology.

07:34 EDT Eightco's Forever 8 signs inventory management agreement with Mobi-hub - Eightco announced that its subsidiary, Forever 8, has renewed and expanded an Inventory Management Agreement with Mobi-hub, a prominent electronics distributor that specializes in premium refurbishment of electronics, most notably, mobile devices. The IMA will guide existing business activities for the upcoming year, as well as provide additional growth opportunities that stand to benefit both companies in the future. The IMA will allow Forever 8 to provide inventory management solutions for Mobi-hub, enabling them to expand their global sales efforts while Mobi-hub focuses on other aspects of their business. "Our expanded IMA with Mobi-hub represents an enhanced driver of growth for Forever 8. Through Mobi-hub's extensive global network, we are well-positioned to rapidly expand our presence in the booming refurbished cellular phone market. This growth opportunity reinforces our commitment to delivering innovative and valuable inventory management solutions to customers around the world," said Eightco Holdings Inc. CEO Brian McFadden.

07:32 EDT Ardelyx announces FDA acceptance for resubmission of NDA of XPHOZAH - Ardelyx announced that the U.S. Food and Drug Administration has accepted its resubmission of a New Drug Application, NDA, for XPHOZAH for the control of serum phosphate in adult patients with chronic kidney disease on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy. The FDA has determined that the NDA is a class 2 review, which results in a six-month review period from the date of resubmission. The FDA has set a user fee goal date of October 17, 2023. The company expects XPHOZAH to be commercially available in the fourth quarter of 2023, as soon as possible following an approval from the FDA. "The acceptance of our NDA is a significant milestone in our journey to bring XPHOZAH to patients. We are excited about the prospect of working collaboratively with the FDA to finalize this review over the next few months," said Mike Raab, president and chief executive officer of Ardelyx. "We are now in full preparation mode and intend to launch XPHOZAH to the physician and patient communities who have patiently waited for access to this novel therapy as soon as possible after we receive an approval notification from the FDA, finally bringing this much-needed treatment to patients."

07:31 EDT B. Riley Financial acquires interest in Scotch & Soda, terms not disclosed - B. Riley Financial announced it has acquired an equity interest in Scotch & Soda through its participation in the recent acquisition of the fashion brand by New York-based brand management company, Bluestar Alliance. Scotch&Soda is a Dutch fashion brand with collections spanning menswear, womenswear, kidswear, denim, eyewear, fragrances, and accessories. Bluestar will continue to operate the brand while expanding its luxury retail distribution strategy and introducing Scotch & Soda to new consumer demographics.

07:17 EDT NioCorp granted extension by OSC to file Q3 financial statements - NioCorp Developments announced that its principal Canadian regulator, the Ontario Securities Commission, has approved an extension to file the Company's third quarter financial statements for the period ended March 31, 2023, the related management's discussion and analysis, and the CEO and CFO certifications relating to the third quarter financial statements through to May 23, 2023. In addition, as a U.S. Securities and Exchange Commission reporting issuer, NioCorp filed a Form 12b-25 Notification of Late Filing with the SEC on May 16, 2023, to provide for a U.S. extension through May 22, 2023 to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023. NioCorp's management is working diligently to remedy the situation and anticipates filing the Required Documents by the Filing Deadlines. Should the Company fail to file the Required Documents by the Canadian Filing Deadline, the Company expects that the OSC will grant a management cease trade order which would restrict all trading in securities of the Company by NioCorp's Chief Executive Officer, Chief Financial Officer, and directors until such time as the Required Documents have been filed by the Company and the MCTO has been revoked. As previously announced on May 11, 2023, the closing of the Company's previously announced business combination with GX Acquisition Corp. II and the high level of complexities in integrating GX and accounting for the Business Combination resulted in the delay in filing the Required Documents.

07:16 EDT Vicinity Motor receives order for 42 Vicinity Classic buses - Vicinity Motor announced the receipt of a new purchase order from global mobility leader Transdev for forty-two Vicinity Classic buses. Per the terms of the supply agreement, Transdev Canada, Inc. has ordered forty-two of the Company's 32-foot Clean-Diesel Vicinity Classic buses for delivery in 2024. The Company anticipates delivering these vehicles leveraging its existing working capital position, supplemented by its working capital lines of credit. The Vicinity buses will service the greater Montreal, Quebec area.

07:11 EDT Virgin Galactic says flight window for upcoming spaceflight will open on May 25 - Virgin Galactic announced that the flight window for its upcoming spaceflight will open on May 25. The Unity 25 mission specialists will begin astronaut training on May 22.

07:10 EDT Next Hydrogen Solutions provides update on cease trade order - The British Columbia Securities Commission issued a cease trade order in respect of its securities as a result of the Company's inability to file its audited annual financial statements and corresponding management's discussion and analysis for the year ended December 31, 2022, including the CEO and CFO certifications, before May 1, 2023 as required by National Instrument 51-102 - Continuous Disclosure Obligations. With the filing of the Financial Documents, it is expected that the CTO will be revoked and the Company is coordinating with the TSX Venture Exchange to coordinate a resumption of trading as expeditiously as possible once the CTO has been revoked. The Company further announces that as a result of the ongoing efforts by the Company's external auditors to prepare the Financial Documents, the Company expects that the filing of its first quarter interim financial report and the Company's Management Discussion & Analysis as at and for the period ended March 31, 2023 may be delayed. While the Company expects the BCSC to revoke the CTO shortly upon filing of the Financial Documents, the Company has applied to the BCSC for a Management Cease Trade Order that will prohibit the management of the Company from trading in the securities of the Company until such time as the Q1 Financials are filed. There is no guarantee that a MCTO will be granted. If the MCTO is granted, the MCTO will prohibit the chief executive officer, the chief financial officer, and possibly the directors, other officers and other insiders of the Company from trading in securities of the Company for so long as the Q1 Financials are not filed. The issuance of such MTCO does not generally affect the ability of persons who are not directors, officers or other insiders of the Company to trade in the Company's securities. No decision has yet been made by the BCSC on this application. The BCSC may grant the application and issue the MCTO or it may impose an issuer cease trade order if the Q1 Financials are not filed in a timely fashion. During the period of default and until filing of the Q1 Financials, the Company intends to satisfy the provisions of the alternative information guidelines as required by National Policy 12-203 - Management Cease Trade Orders. Until the Company has filed the Q1 Financials, members of the Company's management and other insiders are subject to an insider trading black-out policy as per its internal Insider Trading Policy that is consistent with the principles in Section 9 of National Policy 11-207 - Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

07:08 EDT Spectrum regains compliance with Nasdaq minimum bid price requirement - Spectrum Pharmaceuticals announced that on May 16 the Company received a written notification from the Listing Qualifications Staff of the Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1 that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since then, the Staff has determined that for the 10 consecutive business days from May 2 to May 15 , the closing bid price of Spectrum's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

07:08 EDT Virgin Galactic: Flight window for its upcoming spaceflight will open on May 25 - Virgin Galactic announced that the flight window for its upcoming spaceflight will open on May 25. The Unity 25 mission specialists will begin astronaut training on May 22.

07:06 EDT TScan Therapeutics presents preliminary Phase 1 results on TSC-100, TSC-101 - TScan Therapeutics announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor histocompatibility antigen HA-1 and HA-2, respectively, to treat residual disease and prevent relapse following hematopoietic cell transplantation using reduced intensity conditioning in patients with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphocytic leukemia at the American Society of Gene & Cell Therapy 26th Annual Meeting 2023. Gavin MacBeath, Ph.D., acting Chief Executive Officer and Chief Scientific and Operating Officer added: "We are very excited to progress to the second dose level for TSC-101 after seeing encouraging results from the patient at this first dose level. We are hopeful to continue to produce robust clinical outcomes as we progress our Phase 1 trial and remain excited about the potential clinical benefits our engineered T cells may have in difficult-to-treat patient populations." Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting MiHAs HA-1 and HA-2, respectively, to treat residual disease and prevent relapse following HCT using RIC in patients with AML, MDS or ALL. Two control arm patients have been enrolled and received standard of care: Both control arm patients have medium-risk MDS and experienced incomplete donor chimerism following transplant; One patient is now in early stages of relapse: after 100 days, patient-derived cells are still observed and increasing. TSC-101 treatment arm: DL1 administered 21 days after transplant; Engineered T cells showed expansion between 14-21 days after infusion; Detectable markers of activation and proliferation observed; Twenty-one days after treatment and 42 days after transplant, donor chimerism was at 100%. Minimal residual disease assessment: p53 mutation was not detected post-transplant in bone marrow and peripheral blood samples, with sensitivity limit of 0.01%; No DLTs observed. Study advancing to DL2: TSC-100 treatment arm: DL1 administered 28 days after transplant; T cell expansion occurred on Day 7 with detectable markers of T cell activation and proliferation. Two assays are used to detect the action of T cells: MRD: SOC assays measuring remaining malignant cells use flow cytometry, which has a sensitivity of ~0.1%; High sensitivity assay based on next-generation sequencing and droplet digital PCR is also used in this study, with a sensitivity of 0.01%; Chimerism: SOC STR assays have ~1% sensitivity; Study is using the high-sensitivity NGS-based Alloheme assay, with a sensitivity of ~0.13%

07:05 EDT PTC Therapeutics announces primary endpoint achieved in APHENITY trial - PTC Therapeutics announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria, or PKU. "The positive results from the APHENITY trial bring us one step closer to providing a therapy that could deliver meaningful benefit to PKU patients," said Matthew B. Klein, CEO. "The Phe reductions observed in the placebo-controlled portion of the study are consistent with, and, in some cases, exceed the magnitude of Phe reductions recorded in the open label portion of the study. We look forward to meeting with regulatory authorities to discuss the path to approval." The placebo-controlled portion of the study included 98 patients in the primary analysis population. The mean percent Phe reduction in sepiapterin treated patients was 63%. In the subset of classical PKU patients, the mean percent Phe reduction was 69%. Minimal reductions in Phe levels were observed in the placebo treated patients resulting in a highly statistically significant sepiapterin treatment benefit. Sepiapterin was generally well tolerated with no serious adverse events.

07:03 EDT Avidity Biosciences: FDA eases partial clinical hold on AOC 1001 - Avidity Biosciences announced that the U.S. FDA has eased the partial clinical hold on AOC 1001, allowing Avidity to double the number of participants in the MARINA Open-Label Extension study receiving 4 mg/kg of AOC 1001. The FDA is also allowing new participant enrollment for AOC 1001 at 2 mg/kg. Data from the MARINA-OLE study will be used to finalize the AOC 1001 pivotal dose and Phase 3 study design for adults with myotonic dystrophy type 1, an underrecognized, progressive and often fatal neuromuscular disease with no approved treatment options.

07:02 EDT eBay to acquire Certilogo, terms not disclosed - eBay and Certilogo, a provider of AI-powered apparel and fashion goods digital IDs and authentication, announced that eBay has signed a definitive agreement to acquire Certilogo. Certilogo's platform uses digital technology to empower brands and designers to manage the lifecycle of their garments, while providing consumers a seamless way to confirm authenticity, access reliable information about branded items, and easily activate circular services. Closing is subject to satisfaction of customary conditions, including regulatory approvals, and is expected to occur in the third quarter. Further details were not disclosed.

06:47 EDT Innoviz Technologies reports customer aims to expand commercial vehicle program - Innoviz Technologies announced that an existing global automotive customer aims to expand its use of the InnovizTwo LiDAR to an existing light commercial vehicle program. With a mid-decade SOP target, the program is on an accelerated track, with an agreed framework, pending finalizing technical requirements and commercial terms. Potential financial contributions from this program are anticipated to begin this year and played an important role in the decision to update previously communicated 2023 commercial and financial targets. In addition, this collaboration includes an important integration with a major compute platform that we believe could lead to additional expansion opportunities in the future. Innoviz believes that working with autonomy platform partners should enable a faster time to market, accelerate the customer evaluation process, allow more seamless integration with other parts of the software stack, and position Innoviz well in its new customer acquisition efforts.

06:01 EDT Manchester United jumps 8% following reports of higher Qatari offer

05:24 EDT Caravelle receives noncompliance notice from Nasdaq - Caravelle announced that it received a notice from Nasdaq indicating that, as a result of not having timely filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, the company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission.

05:07 EDT Logitech partners with iFixit on reparability efforts - Logitech announced that it is partnering with iFixit, a global repair community that sells replacement parts and provides toolkits and repair guides for consumer electronics devices. Logitech is working with iFixit to facilitate the availability of spare parts, support beyond-warranty repair on select products, and develop relevant repair guides to support this repair.